Cargando…
Sprifermin (rhFGF18) modulates extracellular matrix turnover in cartilage explants ex vivo
BACKGROUND: Sprifermin (recombinant human fibroblast growth factor 18) is in clinical development as a potential disease-modifying osteoarthritis drug (DMOAD). In vitro studies have shown that cartilage regenerative properties of sprifermin involve chondrocyte proliferation and extracellular matrix...
Autores principales: | Reker, Ditte, Kjelgaard-Petersen, Cecilie F., Siebuhr, Anne Sofie, Michaelis, Martin, Gigout, Anne, Karsdal, Morten A., Ladel, Christoph, Bay-Jensen, Anne C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5727954/ https://www.ncbi.nlm.nih.gov/pubmed/29233174 http://dx.doi.org/10.1186/s12967-017-1356-8 |
Ejemplares similares
-
Sprifermin (rhFGF18) versus vehicle induces a biphasic process of extracellular matrix remodeling in human knee OA articular cartilage ex vivo
por: Reker, D., et al.
Publicado: (2020) -
Synovitis biomarkers: ex vivo characterization of three biomarkers for identification of inflammatory osteoarthritis
por: Kjelgaard-Petersen, Cecilie, et al.
Publicado: (2015) -
(99m)Tc-NTP 15-5 is a companion radiotracer for assessing joint functional response to sprifermin (rhFGF-18) in a murine osteoarthritis model
por: Briat, Arnaud, et al.
Publicado: (2022) -
Periodontal surgery using rhFGF‐2 with deproteinized bovine bone mineral or rhFGF‐2 alone: 2‐year follow‐up of a randomized controlled trial
por: Aoki, Hideto, et al.
Publicado: (2020) -
Treatment of intrabony periodontal defects using rhFGF‐2 in combination with deproteinized bovine bone mineral or rhFGF‐2 alone: A 6‐month randomized controlled trial
por: Saito, Atsushi, et al.
Publicado: (2019)